C4 Therapeutics (CCCC) PT Lowered to $53 at BMO Capital, Keeps 'Outperform'
Tweet Send to a Friend
BMO Capital analyst Matthew Luchini lowered the price target on C4 Therapeutics (NASDAQ: CCCC) to $53.00 (from $55.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
